01—Abstract
Summary
Summary of the 8-K filed February 14, 2024. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported fourth-quarter and full-year 2023 results and provided 2024 guidance in a press release furnished under Item 2.02.
Fourth-quarter revenue was $1.01 billiona, versus $1.10 billion in the fourth quarter of 2022, and the filing states organic revenue decreased 3.5%. Fourth-quarter GAAP diluted EPS was $3.62 and non-GAAP diluted EPS was $2.46, with GAAP EPS boosted by a $2.04 per share gain on venture capital and strategic investments, including the Noveprim Group investment. For full-year 2023, revenue rose 3.9% to $4.13 billion, organic revenue grew 6.5%, GAAP diluted EPS was $9.22, and non-GAAP diluted EPS was $10.67.
Management described the 2024 demand environment as cautious and said it believes the current market environment is transitory, expecting constrained client spending to persist in 2024 but stabilizing over the year. The company guided 2024 reported revenue growth of 1.0% to 4.0%, organic growth of 0.0% to 3.0%, GAAP EPS of $7.90 to $8.40b, and non-GAAP EPS of $10.90 to $11.40. The outlook assumes Noveprim contributes at least $0.30 to non-GAAP EPS.
The filing also details the November 30, 2023 acquisition of an additional 41% stake in Noveprim Group, bringing its controlling interest to 90%, for $144.6 million plus up to $55.0 millionc in contingent payments and $12.0 million in deferred payments. Segment results were mixed: Discovery and Safety Assessment organic revenue fell 6.0% in the fourth quarter on a Discovery Services decline, while Manufacturing organic revenue grew 2.3%.
02—Key points
Key Highlights
- Q4 2023 revenue of $1.01 billion, down from $1.10 billion in Q4 2022; organic revenue decreased 3.5%
- Full-year 2023 revenue of $4.13 billion, up 3.9%, with organic growth of 6.5%
- Q4 GAAP diluted EPS of $3.62 included a $2.04 per share gain on venture capital and strategic investments; non-GAAP diluted EPS was $2.46
- Full-year 2023 GAAP diluted EPS of $9.22 and non-GAAP diluted EPS of $10.67
- 2024 guidance: reported revenue growth of 1.0% to 4.0%, organic growth of 0.0% to 3.0%, non-GAAP EPS of $10.90 to $11.40
- Acquired an additional 41% of Noveprim Group on November 30, 2023 for $144.6 million, raising the controlling interest to 90%
- Q4 DSA organic revenue declined 6.0% on a meaningful decline in Discovery Services, while Manufacturing organic revenue grew 2.3%
03—Questions
Frequently Asked Questions
How did Charles River perform in the fourth quarter of 2023?
Revenue was $1.01 billion, a decrease of 7.9% from $1.10 billion a year earlier, and organic revenue decreased 3.5%. GAAP diluted EPS was $3.62 and non-GAAP diluted EPS was $2.46, a decrease of 17.4% from $2.98. The filing attributes the non-GAAP decline mainly to lower revenue and operating income, higher unallocated corporate expenses, and a higher tax rate.
What is the company guiding for 2024?
The company expects reported revenue growth of 1.0% to 4.0% and organic revenue growth of 0.0% to 3.0%. GAAP EPS is estimated at $7.90 to $8.40 and non-GAAP EPS at $10.90 to $11.40. Management expects constrained client spending to persist in 2024 but demand to stabilize over the year.
Why did GAAP EPS exceed non-GAAP EPS in Q4 2023?
GAAP EPS included gains on venture capital and other strategic investments of $2.04 per share, including a gain on the original investment in Noveprim Group. Non-GAAP results exclude these gains, along with acquisition-related amortization and other one-time items.
What did Charles River pay for Noveprim Group and what does it add?
On November 30, 2023, the company acquired an additional 41% equity stake for $144.6 million, plus contingent payments of up to $55.0 million and deferred payments of $12.0 million, bringing its controlling interest to 90%. Noveprim is a provider of non-human primates, and the company expects it to contribute at least $0.30 to non-GAAP EPS in 2024.
04—Continue